naproxen has been researched along with Muscular Dystrophy, Duchenne in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordish-Dressman, H; Miglietta, D; Miller, BK; Nagaraju, K; Ongini, E; Phadke, A; Quinn, JL; Tatem, KS; Uaesoontrachoon, K; Van Der Meulen, JH; Yu, Q | 1 |
| Clementi, E; De Palma, C; Miglietta, D; Ongini, E; Pisa, V; Sciorati, C; Vergani, B; Villa, A | 1 |
2 other study(ies) available for naproxen and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Function Tests; Hindlimb; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Naproxen; Nitric Oxide Donors; Prednisolone | 2014 |
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.
Topics: Animals; Biological Availability; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular Dystrophy, Duchenne; Naproxen; Nitric Oxide Donors | 2015 |